Cas:119838-44-7 tert-butyl (2R)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate manufacturer & supplier

Chemical Name:tert-butyl (2R)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate

CAS.NO:119838-44-7

Synonyms:MFCD00075100;(R)-(+)-1-(tert-Butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone

Molecular Formula:C₁₃H₂₄N₂O₃

Molecular Weight:256.34100

HS Code:2933990090

Physical and Chemical Properties:

Melting point:68-70ºC(lit.)

Boiling point:355.3ºC at 760mmHg

Density:1.064g/cm3

Index of Refraction:1.4365

PSA:49.85000

Exact Mass:256.17900

LogP:1.94350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00075100 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(R)-(+)-1-(tert-Butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(R)-(+)-1-(tert-Butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone Use and application,(R)-(+)-1-(tert-Butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone technical grade,usp/ep/jp grade.

Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. tert-butyl (2R)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate manufacturer ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. tert-butyl (2R)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate supplier The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. tert-butyl (2R)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate vendor Huahai started with the development of characteristic APIs and pharmaceutical intermediates. At the same time, using the international cooperation platform and the opportunity of the expiry of patent protection of major international original research drugs, Huahai has extended the industrial chain to downstream high value-added preparations, and formed intermediates and materials The complete industrial chain of medicine and preparation integration. tert-butyl (2R)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate factory ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.